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Abstract: Oxidative stress constitute one of the commonest mechanism of the secondary 
injury contributing to neuronal death in traumatic brain injury cases. The oxidative 
stress induced secondary injury blockade may be considered as to be a good alternative 
to improve the outcome of traumatic brain injury (TBI) treatment. Due to absence of 
definitive therapy of traumatic brain injury has forced researcher to utilize 
unconventional therapies and its roles investigated in the improvement of management 
and outcome in recent year. Antioxidant therapies are proven effective in many 
preclinical studies and encouraging results and the role of antioxidant mediaction may 
act as further advancement in the traumatic brain injury management it may represent 
aonr of newer moadlaity in neurosurgical aramamentorium, this kind of therapy could 
be a good alternative or adjuct to the previously established neuroprotection agents in 
TBI. 
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Introduction 
Traumatic brain injury (TBI) still remains 
one of the leading causes of death and 
disability, worldwide (1–6). TBI constitutes a 
major global health and socio-economic 
problem with neurobehavioral sequelae 
contributing to long-term disability (7). The 
incidence of TBI progressively continues to 
rapid rising trends and according to 
predictions, the neurotrauma will continue to 
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representing a growing number of deaths 
worlwide by 2020 (8, 9). 
Moderate and severe TBI produces in the 
greatest disability andresponsible for 
consumes the most resources per individual, 
yet magnitude of mild TBI and societal 
ramifications are often underestimated. 
Despite the label “mild”, many of these injuries 
result in immense long-term morbidities10. 
Regarding the mechanisms responsible to 
produce secondary damage of brain tissue 
following TBI, a distinction is made between 
primary and secondary injury mechanisms. 
Primary injury includes the direct effects of the 
mechanical energy on the brain tissue (1, 11). 
The secondary brain injury, which sets in at 
the time of injury and could continue for 
several weeks, is a complex neurodegenerative 
process, involving multiple cellular and 
molecular pathways, including inflammation 
andoxidative stress (3). 
Free radical formation and oxidative 
damage are extensively investigated and 
validated as important contributors to the 
pathophysiology of acute central nervous 
system injury. The generation of reactive 
oxygen species (ROS) and reactive nitrogen 
species (RNS) is an early event following injury 
occurring within minutes of mechanical 
impact (12). Various mechanisms are 
postulated to promote free radical production, 
including glutamate release, intracelular 
calcium overload, increase in arachidonic acid 
and its metabolites, hemoglobin denaturation, 
and iron ion release (1). The production of free 
radicals evoked by brain injury plays a crucial 
role in the initiating and propagating the 
pathogenesis of post-traumatic secondary 
injury, through oxidation and nitration of the 
cellular membrane, proteins, and DNA (3, 13–
16). 
The blockade of oxidative damage seems to 
be a rational intervention to reduce secondary 
brain injury after TBI, and establishing the 
time course of oxidative damage provides 
information on a possible therapeutic window 
for protection against secondary brain injury 
(1, 17, 18). Therefore, to find pharmacological 
agents specifically aiming to inhibit oxidative 
stress and modifying the expression of 
inflammatory cytokines might be a critical 
strategy; thus, antioxidants have been a major 
point for consideration (19). 
Related to the above, the need for news 
therapies for traumatic brain injury is more 
than evident. Therefore, this article aims to do 
a review about the pathophysiology of 
secondary injury, mainly the oxidative stress 
and new proposal of therapies antioxidants 
proposed as a treatment of traumatic brain 
injury. 
Secondary injury mechanisms 
TBI is understood to be the result of 2 
phases: Initial primary neuronal injury 
followed by secondary insults (20). During 
primary injury to the head, it causes rapid 
deformation of brain tissue with destruction of 
brain parenchyma and blood vessels causing 
damage to cell membranes with the immediate 
release of intracellular contents. The initial 
injury event cannot be treated, only prevented 
(21). These effects induce secondary 
mechanisms which are potentially amenable 
to post-injury therapeutic intervention 
because of delayed onset and progression 
course over hours to days and months after the 
initial trauma (22). 
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Secondary brain injury mechanism 
involves a host of cellular and molecular 
cascades that promote cell death include: 
neuronal depolarization, disturbance of ionic 
homeostasis, glutamate excitotoxicity, 
generation of nitric oxide and oxygen free 
radicals, lipid peroxidation (LP), blood-brain 
barrier disruption, ischemia, cerebral edema, 
mitochondrial dysfunction, axonal disruption, 
inflammation, and apoptotic and necrotic cell 
death (23) (figure 1). 
In addition to initiating ischemic and 
apoptotic cell injury cascades, primary brain 
injuries make injured, but salvageable, brain 
tissue vulnerable to secondary brain insults 
(SBIs). These insults are usually well-tolerated 
but, when occurring in an injured brain, can 
lead to further cell death and worsened patient 
outcome. Hypotension, hypoxia and 
hypoglycemia are all examples of SBIs in 
which decreased substrate delivery to an 
injured brain further worsens injury. On the 
other hand, fever, seizures and hyperglycemia 
are examples of SBIs in which increased 
metabolic demand may outstrip 
compensatory mechanisms and result in 
further injury (24). 
The brain is particularly vulnerable to 
oxidative stress because of its high rate of 
oxygen consumption, intensive production of 
ROS, low antioxidant capacity, high level of 
transition metal, and polyunsaturated fatty 
acids (1, 4, 17, 25, 26). Oxidative stress is 
currently thought to be a major contributor to 
the secondary injury cascade following TBI by 
ROS/RNS-induced damage to cellular 
membranes and organelles by lipid 
peroxidation, protein oxidation and 
nucleotide breakdown (21).  
 
 
Figure 1 - Basic concept of primary and secondary 
injury in traumatic brain injury. From: Marklund 
Niklas/British Journal of Pharmacology. Simplistic 
illustration of major preclinical ‘molecular’ secondary 
injury factors as well as clinical secondary injury 
factors (named ‘avoidable factors’ in the neurocritical 
care setting). Early post-injury, glutamate releaseand 
ionic disturbances (Na+, Ca2+ and K+) cause an 
energy metabolic disturbance complicated by an early 
decrease in cerebral blood flow. At this time, 
mitochondrial disturbance is marked and a large 
increase in reactive oxygen/nitrogen species 
(ROS/RNS) is observed. Hyper - or hypocoagulation 
may also be present either causing microthrombosis 
or increased haemorrhages respectively. 
Neuroinflammation and axonal injury is emerging in 
the immediate post-injury phase. Clinically, an 
increased ICP and/or decreased CPP must urgently 
be treated and both too low and too high blood 
glucose levels corrected. It is also crucial that 
hypoxaemia and hypotension, seizures and fever is 
detected and treated. Chronically, marked hormone 
disturbance may be observed. These factors have 
been shown to contribute to the progression of the 
primary injury (indicated by the enlarging circles) 
and may be suitable targets for pharmacological 
intervention to reduce the extent of final injury. 
Ca2+, calcium ions; CPP, cerebral perfusion pressure; 
GLc, Glucose; ICP, intracranial pressure; K+, 
potassium; Na+, sodium; rCBF, regional cerebral 
blood flow 
 
 
 
 
 
 
322 | Romero-Rivera et al - Antioxidant therapies in traumatic brain injury 
 
 
 
 
 
 
 
Reactive oxygen species 
Reactive oxygen species (ROS) are a group 
of chemically reactive molecules derived from 
oxygen (O2) (27). ROS are formed as 
necessary intermediates of metal catalyzed 
oxidation reactions. Atomic oxygen has two 
unpaired electrons in separate orbits in its 
outer electron shell. This electron structure 
makes oxygen susceptible to radical 
formation. The sequential reduction of oxygen 
through the addition of electrons leads to the 
formation of a number of ROS including 
superoxide, hydrogen peroxide, hydroxyl 
radical, hydroxyl ion, and nitric oxide (28). 
At physiological low concentration levels, 
ROS function as redox messengers in 
intracellular signaling and regulation, whereas 
excess of ROS induce oxidative modification 
of cellular macromolecules ie. lipids, proteins, 
nucleic acids and carbohydrates, inhibit 
protein function, and promote cell death. The 
initial reaction generates a second radical, 
which in turn can react with a second 
macromolecule to continue the chain reaction. 
Among the more susceptible targets are 
polyunsaturated fatty acids. Abstraction of a 
hydrogen atom from a polyunsaturated fatty 
acid initiates the process of lipid peroxidation 
(29). 
There are also some mechanisms to 
detoxify radicals. The key metabolic steps are 
superoxide dismutasa (SOD) catalysis of the 
dismutation of superoxide to hydrogen 
peroxide and oxygen and the conversion of 
H2O2 to 2H2O by glutathione peroxidase or 
to O2 + H2O by catalase (30). 
 
Oxidative stress in traumatic brain injury 
Various mechanisms are proposed, which 
have been described to promote free radical 
production, including glutamate release, 
intracellular calcium overload, increase in 
arachidonic acid and its metabolites, 
hemoglobin denaturation, and ionic iron 
release (1). Damaging reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) are 
formed as unavoidable by-products of 
metabolism but their damaging effects are 
normally counteracted by endogenous anti-
oxidant enzymes (e.g. catalase, superoxide 
dismutase, glutathione peroxidase, and 
glutathione reductase) and substances e.g. 
glutathione, metallothionein, vitamin A, 
vitamin C, and vitamin E) (31). Stressors 
arising from traumatic brain injury generate 
an imbalance between free radical production 
and the cells' antioxidant capacity, resulting in 
a state of oxidative stress (32). 
Accumulation of ROS/RNS can result in a 
number of detrimental effects such as lipid 
peroxidation, protein oxidation, and DNA 
damage. Lipid peroxidation disrupts normal 
structure and function of lipid bilayers of the 
cell membrane increasing the permeability. 
Lipid peroxidation may ultimately result in the 
production of multiple aldehyde species (e.g. 
acrolein, malondialdehyde (MDA)) that 
further contribute to toxicity. Protein 
modiﬁcations by accumulated ROS/RNS 
include protein fragmentation, protein 
misfolding, protein–protein cross-linkages, 
production of protein carbonyls, and priming 
of oxidized proteins for proteasomal 
degradation (31). Alteration of different DNA 
structural changes including direct 
 
 
 
 
 
Romanian Neurosurgery (2017) XXXI 3: 319 - 334 | 323 
 
 
 
 
 
 
 
modiﬁcation of nucleotide bases, formation of 
apurinic/apyrimidinic sites, DNA single 
strand breaks and double strand breaks. 
Guanine is the most susceptible to oxidative 
modiﬁcations due to the fact that it has the 
lowest reduction potential. Hydroxyl radicals 
have been shown to interact with the C4, C5, 
and C8 positions in the imidazole ring of 
guanine forming of 8-hydroxyguanosine (8-
OxoG). Peroxynitrite is also capable of 
reacting with guanine to form 8-nitroguanine. 
It is known that preferential target of oxidative 
damage are telomeres. For example, TRF2 may 
prevent ATM-mediated initiation of oxidative 
DNA damage signaling, POT1, which 
maintains stability of telomeric ends, is also 
known to inhibit another DNA damage kinase 
ATR. Both ATM and ATR are known to 
initiate apoptotic neuronal death in the 
context of DNA damage through activation of 
p53 (31). 
Neuroprotection and emerging roles of 
Nrf2 
Not all mediators induced in the peri-
lesional zones necessarily contribute to 
celllular death. As is the case for damage-
inducing pathways, protective pathways also 
appear to be similar if not identical in ischemic 
and traumatic injury. These mediators possess 
damage-reducing properties and represent 
endogenous efforts to counteract ischemic or 
traumatic damage and improve neuronal 
repair. Some of the protective mechanisms 
include: 1) Heat shock proteins (HSPs). They 
are induced early after ischemic onset and 
their induction prior to ischemia may confer 
ischemic tolerance. 2) Anti-inflammatory 
cytokines. Certain cytokines have anti-
inflammatory capabilities such as IL-10 may 
be protective against ischemic damage, mainly 
by inhibiting production of the inflammatory 
cytokines. 3) Growth factors. Nerve growth 
factor (NGF), brain derived neurotrophic 
factor (BDNF), glial derived growth factor 
(GDNF), basic and acidic fibroblastic growth 
factors (FGF) and members of the 
transforming growth factor super family 
(TGF). These growth factors are thought to 
confer protection mainly by interfering with 
apoptotic pathways and preventing apoptotic 
death. 4) Erythropoietin. This kidney-derived 
cytokine acts as a growth factor and inhibits 
apoptotic cell death. 5) Sex hormone. Estrogen 
was shown to protect the brain from 
experimental cerebral ischemia, likely through 
both vascular and neuronal cellular 
mechanisms. 6) Endogenous antioxidant 
mechanisms. Antioxidant enzymes and low-
molecular-weight antioxidants are all induced 
in the early hours following ischemia and 
trauma. Such antioxidants include Mn-SOD 
(superoxide dismutase), extracelular SOD and 
Cu-Zn-SOD and also gluthatione (33). 
There are few current researches showing 
excessive generation of oxygen free radicals 
after is the core pathological link leading to the 
nerve cell injury and apoptosis. NF-erythroid 
2-related factor 2 (Nrf2) is a recently 
discovered nuclear factor. In physiological 
state, it is mainly located in the cytoplasm and 
forms a complex combining with cytoplasmic 
protein Keapl. When oxidative stress stimulus 
occurs, it is decoupled with Keapl through 
phosphorylation, transfers into nucleus, 
combines with antioxidant response element 
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(ARE) sequence, forms Nrf2/ARE pathway 
and then starts the gene expression of phase II 
detoxifying enzymes and antioxidases (H0-1, 
NQO1, etc) regulated by ARE. Nrf2/ARE 
pathway plays an important role in 
endogenous anti-oxidation process in vivo 
and can be induced by external factors (14). 
Yan Wei at el. demonstrated the activation 
of Nrf2–ARE pathway occurs after TBI. 
Moreover, emerging evidence suggests that 
NRF2, in addition to its antioxidant functions, 
may also play an important role in regulating 
inflammation in the brain. These findings 
connect NRF2 not only to an elevated anti-
oxidant capacity but also to expression of 
other types of protective proteins i.e. brain 
derived neurotrophic factor, the anti-
apoptotic B-cell lymphoma 2, the anti-
inflammatory interleukin (IL)-10, the 
mitochondrial transcription (co)-factors NRF-
1 and peroxisome proliferator-activated 
receptor gamma coactivator1-alpha (PGC-1a), 
the iron exporter ferroportin 1, and the 
autophagic protein p62 (36, 34). 
Nrf2 activation also protects the blood 
brain barrier during TBI. TBI causes a biphasic 
opening of the BBB. The first opening used 
happens within hours (acute phase) after TBI 
and the other secondary phase peaks 1–3 days 
after injury. The latter opening is associated 
with a loss of endothelial cells and tight 
junction proteins. Enhanced Nrf2 staining can 
be detected in the blood brain barrier 
following TBI (35). 
It was demonstrated that the 
patientsdeficient (Nrf2-/-) mice exhibited 
poorer outcomes than the wild-type mice, 
while administration of tBHQ or histone 
deacetylase inhibitors could protect against 
TBI by activation of Nrf2. These evidences 
demonstrate that activation of the Nrf2–ARE 
pathway is beneficial for TBI. (16) It is now 
accepted that the Nrf2–ARE pathway can be 
regulated in many different ways (14, 16, 36). 
Antioxidant therapeutic strategies 
The gradual processes of secondary injury 
may provide doctors with so-called ‘‘golden 
hour’’ wibndowfor pharmacological based 
intervention, and a lot of agents and 
compounds targeting secondary brain injury 
factors are shown to be protective in 
experimental TBI models3. However, clinical 
trials for neuroprotective therapies of TBI still 
continue to have a high failure rate (37). 
Several researches have described the 
antioxidant mechanism of some agents, but 
most of them have unfortunately failed in their 
efforts to provide neuroprotection in 
moderately to severely injured TBI patients. 
Some of these therapies have demonstrated 
inadequacies include polyethyleneglycol-
conjugated-SOD (PEG-SOD) and tirilazad. 
The non-glucocorticoid LP inhibitor tirilazad, 
which inhibits LP propagation reactions by 
membrane stabilization and scavenging LOO• 
was tested as a TBI therapeutic in the early 
1990s. Factors contributing to the failure of the 
tirilazad study were the apparent inability of 
the agent to cross the blood–brain barrier in 
high enough concentrations in severely 
injured patients as well as gender differences in 
treatment outcomes and drug metabolism. On 
the other hand, PEG-SOD was limited in its 
therapeutic value based on its large size and 
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rather narrow therapeutic window to scavenge 
the short-lived primordial O2•− radical (12). 
Edaravone (3-methyl-1-phenyl-2-
pyrazolin-5-one) is a derivative of antipyrin 
and was approved as free radical scavenger. 
Edaravone was first reported to strongly 
scavenge hydroxyl radicals (OH−) produced 
by the Fenton reaction in vitro and to decrease 
lipid and L-tyrosine oxidation. Edaravone was 
used in other neural injury models such as 
spinal cord injury, TBI, and brain 
hemorrhage38. However, in a study conducted 
by Pratyush Chaudhuri, no significant 
difference was observed in the outcome scales 
between the group administered edaravon and 
the group not administered edaravon. On the 
other hand, the mortality rate was also higher 
in the edaravon group. The possible etiology 
from this investigation was the drug induced 
hepatic dysfunction resulting in persistently 
reduced serum albumin levels and thereby 
causing a decrease in the circulating volume 
(39). 
Numerous experimental studies in recent 
years have suggested that erythropoietin 
(EPO) is an endogenous mediator of 
neuroprotection in various central nervous 
system disorders, including TBI (18). 
Erythropoietin is a glycoprotein and cytokine 
of 34kDa which is produced mainly by the fetal 
liver and the adult kidney in response to 
hypoxia. Erythropoietin (EPO) and the EPO 
receptor (EPOR), are also expressed in the 
brain. While EPO and EPOR are only weakly 
expressed in normal adult brain, expression of 
EPO and EPOR is greatly increased in 
response to different types of brain injury. 
Inhibition of EPO activity by the 
administration of soluble EPORs worsens the 
severity of neuronal injury, suggesting that 
endogenous EPO is directly involved in an 
intrinsic neuronal repair pathway (40). 
Because of the potential thromboembolic 
complications caused by EPO, it may be 
difficult to achieve neuroprotection with EPO 
in TBI patients without further increasing 
potentially life-threatening complications. 
However, development of derivatives of EPO 
that do not bind to the classical EPOR 
(carbamylatederythropoietin or CEPO) or that 
have such a short half-life in the circulation 
that erythropoiesis is not significantly 
stimulated (asialoerythropoietin or 
neuroerythropoietin) have clearly 
demonstrated that the neuroprotective effects 
of EPO can be separated from the 
hematopoietic effects18. Specifically, the 
receptor complex mediating the 
neuroprotective effects of EPO has been 
reported to be associated with the common 
receptor (cR) subunit, also known as CD131, 
which is the signal-transducing component 
used by the granulocyte macrophage colony 
stimulating factor (GM-CSF), IL-3, and IL-
5receptors (41). 
Current promising antioxidant 
therapies  
Currently, there is no neuroprotective 
agent, which demonstrated improved 
neurological outcomes in a large phase III 
clinical trial. Efforts should focus on 
developing novel strategies, with thorough 
preclinical studies and clinical trials that 
consider the translational barriers of a 
heterogeneous pathology such as TBI. The 
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potential use of unconventional treatments, 
such as antioxidant defense system 
reinforcement, could play a key role in the 
management. This reinforcement appears as a 
safe, low-cost and multifunctional novel 
therapeutic approach in TBI patients. 
Antioxidant therapies are effective over a long 
period of time, allowing for suitable use in 
clinical settings. Due to the encouraging 
preclinical results and the antioxidant drug 
proﬁles, acute antioxidant reinforcement is 
emerging as a highly cost-effective alternative 
for neuroprotection in TBI patients (42). 
U-83836E 
The 21-aminosteroids (lazaroids) are a new 
family of steroid compounds, which inhibit 
lipid peroxidation reactions. They are novel 
antioxidant agents, which have been shown to 
prevent free radical-mediated blood-brain 
barrier damage (43). 
U-83836E is a second-generation lazaroid 
with a non-steroidal structure characterized by 
a ring portion of alpha-tocopherol bonded to 
various amine groups. Its structure enables the 
dual functionality of LP inhibition and 
scavenging LOO•, thereby making it much 
more effective than the endogenous scavenger 
vitamin E44. U-83836E treatment can 
attenuate post-traumatic LP in cerebral 
cortical tissue or mithochondria together with 
a preservation of aerobic respiratory function 
and Ca++-buffering capacity (45). More 
recently U-83836E has also been shown to 
inhibit calpain-mediated cytoskeletal 
degradation signifying the intricate 
relationship between post-traumatic LP, 
disruptions in neuronal Ca2+ homeostasis and 
calpain-mediated cytoskeletal damage (12). If 
U-83836E given prophylactically, enhances 
Na+/K+ and Mg2+/Ca2+-ATPase activities 
and attenuates edema in cerebral trauma in 
rats (46). 
U-83836E also has been shown to inhibit 
protein nitration (3-NT) in injured cortical 
tissue and mitochondria even though it does 
not interact directly with the reactive nitrogen 
species peroxynitrite. Further studies to 
determine the pharmacokinetics of U-83836E 
in humans are strongly recommended, as the 
compound appears to inhibit a crucial step of 
the secondary brain injury cascade of events 
(42). 
Resveratrol 
Resveratrol (3, 4’, 5-trihydroxystilbene) is a 
phytoalexin polyphenolic structurally related 
to stilbenes. It is found in two isomers, cis- (z) 
and trans- (E) resveratrol47. Resveratrol is 
present in relatively large amounts in grapes 
and red wine and, to a much lesser extent, in 
white wines (47–50). Many studies have 
demonstrated resveratrol has a wide range of 
pharmacological properties, including 
antioxidant, cardioprotective and anticancer 
effects. In addition to these beneﬁcial actions, 
resveratrol also noted for its anti-
inﬂammatory, immunomodulatory, 
chemopreventive and neuroprotective 
activities. In this respect it has been shown that 
resveratrol readily crosses the intact blood–
brain barrier (48). Recently, resveratrol was 
found to be a potent neuroprotective agent 
against excitotoxicity, ischemia, and hypoxia, 
in both in vitro and in vivo models (51). 
Resveratrol has demonstrated efficacious 
in reducing neuropathological and behavioral 
sequelae. Some studies have also found that 
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traumatic brain injury (TBI) in both adult and 
immature animals is amenable to treatment 
with resveratrol (52, 55). In rat traumatic brain 
injury, a single high dose of resveratrol (100 
mg/kg) administerd immediately after trauma 
reduced brain edema and oxidative stress, and 
attenuated brain pathology 14 days later (49). 
Many different pathways determining the 
possible actions of resveratrol have been 
proposed including anti-inflammatory 
properties, inhibition of NO toxicity, 
induction of neuroprotective enzymes such as 
heme oxygenase-1 (HO1), free radical 
scavenging, NF-kB mediated suppression of 
proinflammatory genes, upregulation of eNOS 
and VEGF, inhibition of MMP-9, and by 
mimicking ischemic preconditioning via the 
sirtuin pathway (53). A relationship exists 
between HO1 and NOS. The nuclear factor-
erythroid-2-related factor 2 (Nrf2) regulates 
HO1 transcription, which acts as a scavenger 
of NO and an inhibitor of iNOS. It has been 
reported that resveratrol modulates HO1 and 
iNOS expression in glial cells, so HO1 can also 
be critical to signaling the antioxidant 
response of resveratrol (54). 
Allicin 
Allicin (which formed by the interaction of 
the enzyme alliinase with its substrate alliin) is 
responsible for most of active ingradient of 
garlic. Allicin treatment has showed decrease 
the expression of TNF-α. Some studies have 
reported a significant reduction of brain water 
content when allicin administrated 2 or 4 h 
after injury, but not when the administration 
is delayed by 8 h. Treatment with allicin can 
reduce brain edema, attenuate neurological 
deﬁcit and inhibit TBI-induced apoptotic 
neuronal death (3). 
Edaravone 
Edaravone, a free radical scavenger, 
suppresses axonal injury and oxidative stress 
in the cortex, corpus callosum, and 
hippocampus 24h after injury. The 
neuroprotective effects of edaravone were 
observed in mice receiving 1.0, 3.0, or 10 
mg/kg immediately after impact. With 
treatment 1 h after impact, axonal injury was 
also signiﬁcantly suppressed and this 
therapeutic effect persisted up to 6 h after 
impact. Edaravone therapy protects against 
memory deﬁcits following TBI mediated by 
suppression of traumatic axonal injury and 
oxidative stress (13). 
Tempol 
Tempol (4-hydroxy-2, 2, 6, 6-
tetramethylpiperidine-N-oxyl) is a water-
soluble stable and paramagnetic nitroxyl 
radical or nitroxide. Tempol is a SOD mimetic, 
and hence an efﬁcient scavenger of free 
radicals. Endogenous SOD is a much more 
efﬁcient antioxidant than vitamins, since the 
rate constant for interaction of SOD with O2− 
is about 1.6–2.4x109mol L−1 s−1, whereas that 
of vitamin E with O2− approximates 0.59 mol 
L−1 s−1. Tempol is therefore not as powerful 
as endogenous SOD, but it is much more 
powerful than vitamins (55). 
The neuroprotective effects of tempol is 
reported in both models of TBI and spinal cord 
injury. In the mouse Controlled cortical 
impact (CCI) TBI model, tempol reduced 
post-traumatic LP and protein nitration-
induced oxidative damage, which resulted in 
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preserved mitochondrial bioenergetics, 
reduced calpain-mediated cytoskeletal 
damage and reduced neurodegeneration (12). 
Tempol showed cerebroprotective effects in 
terms of limiting edema formation, 
ameliorating blood–brain barrier disruption, 
and improving functional recovery. It has been 
concluded that the beneficial effects of tempol 
were because of its catalytic scavenging of 
superoxide radicals. More recent experiments 
have suggested that an important antioxidant 
property that may contribute significantly to 
the inhibition of posttraumatic oxidative 
damage in brain tissue involving catalytic 
scavenging of the PN-derived radicals ●NO2 
and ●CO3 (56). 
Tempol can shuttle between the nitroxide 
radical, the reduced hydroxylamine and the 
oxidized oxoammonium cation form with 1 
and 2 electron transfer reactions. These are 
facilitated by “boat and chair” conformational 
changes that underlie the rapidity and catalytic 
nature of the reactions. The reaction of tempol 
with superoxide anion (O2•−) to form 
hydrogen peroxide (H2O2) accounts for its 
“superoxide dismutase (SOD) mimetic” 
action. Tempol is effective as a catalase-like 
agent in preventing the generation of•OH 
from H2O2 in the presence of transition 
metals in the Fenton reaction and it has high 
capacity to permeate cell membranes, the 
gastrointestinal tract (GIT) or the blood-brain 
barrier which accounts for its effectiveness 
after oral administration and central nervous 
system actions57. Previous studies have shown 
that tempol can decrease brain 3-NT after 
controlled cortical impact-induced TBI (CCI-
TBI), but only if administered during the ﬁrst 
hour. Thus, attempting to block PN formation 
by either inhibiting •NO synthesis or 
scavenging PN radicals does not appear to be a 
practical therapeutic approach to reducing 
early PN-mediated oxidative damage from a 
therapeutic window point of view58. However, 
effects of tempol remains promising and 
requires further investigation. In addition, 
tempol may be an ideal candidate for 
combination therapy with other 
neuroprotective approaches (12). 
Melatonin 
Melatonin (N-acetyl-5-
methoxytryptamine), a hormone secreted 
from pineal gland and synthesized from 
tryptophan or formed as the metabolic end 
product of serotonin, is a non-enzymatic 
antioxidant and neuroprotective agent. 
Melatonin has been shown to exert 
neuroprotection in several central nervous 
system disease models, including brain and 
spinal cord trauma, cerebral ischemia, 
subarachnoid hemorrhage, and intracerebral 
hemorrhage (59). Melatonin is a major 
molecule in protecting membrane 
constituents from oxidative agents. This 
molecule also optimizes the physiology of 
membrane receptors and channels as well as 
maintaining the shape of the cell. The effects of 
melatonin as a potent protective substance in 
post-TBI injuries have been shown in both in 
vivo and in vitro studies. It has been 
recognized that melatonin administration in 
both low and high doses can signiﬁcantly 
decrease brain edema and blood-brain barrier 
permeability at 72 h after TBI. Moreover, this 
inhibitory effect is associated with 
improvement of neurologic scores (60). 
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Melatonin is also well tolerated even at supra-
physiological doses (61). 
Melatonin is a signiﬁcant free radical 
scavenger and antioxidant at both 
physiological and pharmacological 
concentrations in vivo. Like other secondary 
metabolites, melatonin exerts antioxidant 
properties as a direct free radical scavenger 
and by stimulating antioxidant enzymes. 
Indeed, melatonin is able to scavenge H2O2 in 
a dose-dependent manner. Moreover, the 
biological activities of melatonin metabolites 
N(1)-acetyl-N(2)-formyl-5-
methoxykynuramine (AFMK) and N1-acetyl-
5-methoxykynuramine (AMK) have been 
described. AFMK is a potent antioxidant 
providing protection to DNA and lipids 
viaseveral mechanisms. AMK is also a potent 
antioxidant and inhibits prostagladin 
biosynthesis. Melatonin can scavenge other 
reactive oxygen species such as ONOO, NO 
and H2O2. Additionally, due to its 
amphiphilic structure, melatonin has no 
barriers of distribution and may have the 
advantages of having a lower side effect proﬁle 
and producing fewer pharmacokinetic or 
phamacodynamic interactions compared to 
xenobiotic antioxidants (62–64). 
Mammalian target of rapamycin (mTOR) 
pathway is an essential cellular signaling 
pathway involved in a number of important 
physiological functions like cell growth, 
proliferation, metabolism, protein synthesis 
and autophagy. Activation of microglia 
following TBI might results-frodue to m cell 
proliferation or size enlargement induced by 
phosphorylation and activation of mTOR 
pathway. In previous studies in rodents, p-
mTOR, p-p70S6K and p-S6RP were markedly 
increased in ipsilateral cortex 24 h post-TBI in 
mice, suggesting activation of mTOR pathway 
following TBI. It has also showed that 
injection of melatonin repressed 
phosphorylation of mTOR and its 
downstream substrates. Furthermore, 
melatonin restrained the activation of 
microglia and decreased protein expression of 
IL-1b and TNF-α, thereby increasing the 
number of neurons in peri-contusive cortex at 
24 h after TBI (65). 
Melatonin has been shown to promote 
Nrf2 protein translocation from the cytoplasm 
to the nucleus and to prevent antioxidant 
enzyme activities decline, including 
superoxide dismutase and glutathione 
peroxidase66. 
Some studies have proved combination 
therapy with melatonin and other therapies. 
The therapy with melatonin (10 mg/kg) and 
dexamethasone (0.025 mg/kg) is signigficantly 
able to reduce edema and brain infartions (67). 
Sulforaphane 
Recently, the Nrf2 signaling pathway, 
which is been considered an endogenous 
antioxidant mechanism in the cellular defense 
against oxidative or electrophilic stress, has 
generated increasing interest. The ability to 
induce phase 2 detoxifying genes and 
antioxidant enzymes at the transcriptional 
level could have significant advantages over 
more conventional approaches. Previous 
studies have shown that the Nrf2-ARE 
pathway was activated in the brain and played 
an important role in limiting inflammation 
and apoptosis after TBI (68). 
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Sulforaphane, a naturally occurring 
compound generated from cruciferous 
vegetables such as broccoli, is a potent inducer 
of antioxidant and detoxifying enzymes. As 
such, this compound has been suggested to 
provide broad protection against a variety of 
cellular threatseg. example, application of 
sulforaphane to neuron-astrocyte co-cultures 
protects neurons against nonexcitotoxic 
glutamate and hydrogen peroxide toxicity. 
These beneficial effects of sulforaphane have 
been shown to involve induction of Nrf2-
driven genes (69–71). 
Activation of the transcription factor NF-
E2-related factor-2 (Nrf2) by sulforaphane, 
increase the expression of endogenous 
cytoprotective genes in brain tissue and 
microvessels. Post-injury administration of 
sulforaphane reduce the loss of endothelial cell 
markers and tight junction proteins and 
preserve blood–brain barrier function. These 
protective effects are dependent on the activity 
of Nrf2 (72). 
In vitro studies, sulforaphane is 
demonstrated to disrupt the Nrf2/Keap1 
interaction, leading to Nrf2 stabilization and 
nuclear localization and the expression of 
ARE-containing phase II genes, which play a 
major role in the detoxiﬁcation of ROS 
produced by xenobiotics (42, 73). 
Some of the effects related to the use of 
sulforaphane are only observed when the 
treatment is initiated within the first hr, but 
not 6 hr, post-injury (69). Several studies 
support the use of sulforaphane in the 
treatment of TBI, and the fact that Nrf2 
activation may be a prime candidate for the 
attenuation of oxidative stress and subsequent 
neurotoxicity. Nevertheless, considering the 
narrow time window of sulforaphane use 
observed in preclinical studies, the success of 
sulforaphane in clinical settings is 
uncertain42. 
Vitamin C and vitamin E 
Vitamin C (ascorbic acid, ascorbate) is a 
potent watersoluble antioxidant in humans. It 
also behaves as an enzyme modulator, causing 
the up-regulation of endothelial NOS (eNOS) 
and down-regulation of NADPH oxidase. 
Antioxidant and pharmacodynamic 
properties allow ascorbate to protect neurons 
from NMDA-induced excitotoxicity and to 
prevent lipid peroxidation induced by various 
oxidizing agents, especially in combination 
with a-tocopherol, in cell cultures. 
Interestingly, there is one clinical trial of 
vitamin C involving in patients with severe 
TBI and the radiologic diagnosis of diffuse 
axonal injury. Patients received a total dose of 
32 g of intravenous vitamin C during the ﬁrst 
7 days after TBI, with a maximum single dose 
of 10 g on the ﬁrst day, resulting in a signiﬁcant 
earlier stabilization of the perilesional edema 
compared with the placebo group. Although 
the absence of many parameters of Clinical 
importance and monitoring techniques may 
make the interpretation of these results 
challenging, although encouraging results 
regarding the use of vitamin C in humans (42). 
On the other hand, Vitamin E, mainly 
alpha-tocopherol, is the major peroxyl radical 
scavenger in biological lipid phases such as cell 
membranes, and its antioxidant mechanism is 
related to the inhibition of lipid peroxidation 
and NADPH oxidase. One clinical trial of 
vitamin E has been performed in patients with 
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severe TBI and the radiologic diagnosis of 
diffuse axonal injury. For 7 days, patients 
received vitamin E at 400 IU/day 
intramuscularly, which resulted in improved 
clinical outcome and reduced mortality at 
discharge. Despite promising results, clinical 
trials using vitamins C and E, isolated or in 
combination, are needed to change current 
therapeutic measures in patients suffering TBI 
(42). 
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